The Importance of Genetic Mutation Screening to Determine Retransplantation Following Failed Kidney Allograft from Recurrent Atypical Haemolytic Ureamic Syndrome

Overview

Journal BMJ Case Rep

Specialty General Medicine

Date 2014 Mar 28

PMID 24671321

Citations 2

Authors

Samantha Chua

Germaine Wong

Wai Hon Lim

Affiliations

Soon will be listed here.

Abstract

We report the case of a patient with familial atypical haemolytic uraemic syndrome (aHUS) who underwent successful retransplantation 30 months following his failed first kidney allograft from recurrent aHUS. He achieved excellent graft function (creatinine 90 μmol/L), with no evidence of disease recurrence on standard maintenance immunosuppression 9 months after his second deceased donor kidney transplantation. Genetic mutation testing was not available prior to first transplant but screening prior to retransplant identified the patient as having a newly discovered mutation, c.T3566A, within exon 23 of the complement factor H (CFH) gene. Currently, public financing and subsidisation for eculizumab, a costly but effect complement (C5) inhibitor for the treatment of aHUS is not available in Australia. The decision for retransplantation must balance between the risk of disease recurrence and greater risk of death on dialysis. The absence of a more severe CFH genotype assisted in the decision for retransplantation and suggests the importance of genetic mutation screening in order to stratify the risk of disease recurrence and graft loss versus the benefit of transplantation.

Citing Articles

Thrombotic microangiopathy after renal transplantation: Current insights in and recurrent disease.

Abbas F, Kossi M, Kim J, Sharma A, Halawa A World J Transplant. 2018; 8(5):122-141.

PMID: 30211021 PMC: 6134269. DOI: 10.5500/wjt.v8.i5.122.

Salvadori M, Bertoni E World J Transplant. 2017; 6(4):632-645.

PMID: 28058212 PMC: 5175220. DOI: 10.5500/wjt.v6.i4.632.

References

Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinaglio P . Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant. 2005; 5(5):1146-50. DOI: 10.1111/j.1600-6143.2005.00783.x. View

Jalanko H, Peltonen S, Koskinen A, Puntila J, Isoniemi H, Holmberg C . Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant. 2007; 8(1):216-21. DOI: 10.1111/j.1600-6143.2007.02029.x. View

Davin J, Strain L, Goodship T . Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol. 2008; 23(9):1517-21. PMC: 2459233. DOI: 10.1007/s00467-008-0833-y. View

Hirt-Minkowski P, Schaub S, Mayr M, Schifferli J, Dickenmann M, Fremeaux-Bacchi V . Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option?. Nephrol Dial Transplant. 2009; 24(11):3548-51. DOI: 10.1093/ndt/gfp377. View

Saland J, Emre S, Shneider B, Benchimol C, Ames S, Bromberg J . Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant. 2006; 6(8):1948-52. DOI: 10.1111/j.1600-6143.2006.01375.x. View

Noris M, Remuzzi G . Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens. 2013; 22(6):704-12. DOI: 10.1097/MNH.0b013e328365b3fe. View

Noris M, Remuzzi G . Atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 361(17):1676-87. DOI: 10.1056/NEJMra0902814. View

Stegall M, Diwan T, Raghavaiah S, Cornell L, Burns J, Dean P . Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011; 11(11):2405-13. DOI: 10.1111/j.1600-6143.2011.03757.x. View

Pickering M, Goicoechea de Jorge E, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose K . Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med. 2007; 204(6):1249-56. PMC: 2118613. DOI: 10.1084/jem.20070301. View

10.

Saland J, Shneider B, Bromberg J, Shi P, Ward S, Magid M . Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2008; 4(1):201-6. PMC: 2615708. DOI: 10.2215/CJN.02170508. View

11.

Ranghino A, Tognarelli G, Basso E, Messina M, Manzione A, Daidola G . A newly identified mutation in the complement factor I gene not associated with early post-transplant recurrence of atypical hemolytic-uremic syndrome: a case report. Transplant Proc. 2013; 45(7):2785-7. DOI: 10.1016/j.transproceed.2013.07.012. View

12.

Saland J, Ruggenenti P, Remuzzi G . Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2008; 20(5):940-9. DOI: 10.1681/ASN.2008080906. View

13.

Remuzzi G, Ruggenenti P, Codazzi D, Noris M, Caprioli J, Locatelli G . Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet. 2002; 359(9318):1671-2. DOI: 10.1016/S0140-6736(02)08560-4. View

14.

Risitano A . Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol. 2013; 735:155-72. DOI: 10.1007/978-1-4614-4118-2_10. View

15.

Davin J, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T . Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis. 2009; 55(4):708-11. DOI: 10.1053/j.ajkd.2009.08.011. View

16.

Zuber J, le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C . New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2010; 7(1):23-35. DOI: 10.1038/nrneph.2010.155. View

17.

Schubert J, Hillmen P, Roth A, Young N, Elebute M, Szer J . Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2008; 142(2):263-72. PMC: 7440627. DOI: 10.1111/j.1365-2141.2008.07183.x. View

18.

Barnett A, Asgari E, Chowdhury P, Sacks S, Dorling A, Mamode N . The use of eculizumab in renal transplantation. Clin Transplant. 2013; 27(3):E216-29. DOI: 10.1111/ctr.12102. View

19.

Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S . Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013; 24(3):475-86. PMC: 3582207. DOI: 10.1681/ASN.2012090884. View

20.

Brodsky R, Young N, Antonioli E, Risitano A, Schrezenmeier H, Schubert J . Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 111(4):1840-7. DOI: 10.1182/blood-2007-06-094136. View